Axsome Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
FDA approved AUVELITY as the first non-antipsychotic for agitation in Alzheimer's dementia, based on robust efficacy and safety data. Launch is set for June with strong insurance coverage and high anticipated compliance, addressing a major unmet need for millions of patients and caregivers.
-
Strong 2025 sales and operating leverage set the stage for 2026, with a major PDUFA date for Auvelity in Alzheimer's agitation on April 30, 2026. The company is doubling its field force, advancing a robust late-stage pipeline, and expanding market access for key CNS products.
-
Auvelity continues strong growth with expanded sales force and broadening market access, while preparations advance for ADA agitation approval and new indications. Pipeline progress includes new trials for fibromyalgia, epilepsy, and narcolepsy, with multiple late-stage and early-stage programs advancing.
-
AUVELITY continues strong growth with plans to double its sales force and expand indications, including Alzheimer's agitation pending FDA review. The pipeline is robust, with imminent NDA submissions for AXS-12 and ongoing development of Sunosi and AXS-14, targeting large, underserved markets.
-
Auvelity surpassed $500 million in sales, driven by expanded market access and a doubling of the sales force to 600 reps. The pipeline is advancing with an sNDA for Alzheimer's agitation under FDA review, new clinical trials, and strategic in-licensing, while financials approach cash flow positivity.
Fiscal Year 2025
-
Revenue grew 66% year-over-year to $639M, driven by Auvelity, Sunosi, and Symbravo. Auvelity surpassed $500M in sales, and the pipeline advanced with new trials and an acquisition. Cash reserves of $323M support operations into profitability.
-
Awaiting FDA decision for Auvelity in Alzheimer's agitation, with robust clinical data supporting the submission. Commercial expansion is planned for both MDD and ADA, with strong market access and DTC efforts driving prescription growth. Pipeline progress includes multiple late-stage and early-stage programs.
-
Q3 saw strong sales growth across key products, with AUVELITY and SUNOSI leading performance and a successful DTC campaign boosting prescriptions. Regulatory progress continues for ADA and narcolepsy, while financials turned cash flow positive and operating leverage is expected to improve.
-
Q3 2025 saw 63% year-over-year revenue growth to $171M, led by AUVELITY, SUNOSI, and SYMBRAVO. Pipeline progress included a supplemental NDA for AXS-05 in Alzheimer's agitation and multiple late-stage trials. Cash reserves of $325.3M support operations into cash flow positivity.
-
Q2 saw strong commercial growth, with Auvelity and Symbravo launches supported by expanded sales force and coverage. R&D pipeline advanced with key regulatory filings, while feedback on Alzheimer’s agitation program remains positive. Peak sales for new indications are projected to surpass current products.
-
Three commercial products are driving strong revenue growth, with AUVELITY expanding access and SYMBRAVO launching in migraine. The pipeline is robust, with key regulatory filings for AXS-05 in Alzheimer’s agitation and AXS-12 in narcolepsy, and disciplined R&D and commercial strategies support continued momentum.
-
Q2 net sales reached $150 million, driven by Auvelity and Sunosi, with SYMBRAVO newly launched. Regulatory filings for AXS-05 and AXS-12 are on track, and market access for Auvelity expanded by 28 million lives. Growth is expected across all products, with robust clinical data supporting differentiation.
-
Strong Q2 sales and robust cash position support ongoing growth across CNS-focused products. Auvelity's sNDA for Alzheimer's agitation is on track, with significant market potential, while Simbrivo and Sunosi expand through targeted launches and pipeline development.
-
Q2 2025 saw $150M in revenue, up 72% year-over-year, driven by Auvelity and Sunosi growth and the launch of Symbravo. Net loss narrowed to $48M, and major pipeline milestones remain on track, with expanded payer coverage and strong commercial execution expected to drive further growth.
-
The event highlighted a robust CNS pipeline with multiple late-stage programs, including Auvelity, AXS-05, Sunosi, AXS-12, AXS-14, and Symbravo, all showing strong clinical efficacy and safety. The company targets over $16B in annual peak sales, with several regulatory submissions and launches planned through 2028.
-
Focused on CNS disorders, the company is advancing a diverse pipeline with three commercial products and several late-stage programs targeting major unmet needs. Key regulatory filings, new launches, and robust financials position it for significant growth through 2027.
-
Multiple commercial and late-stage CNS programs are advancing, with imminent launches and regulatory filings planned for migraine, Alzheimer’s agitation, narcolepsy, and fibromyalgia. Growth is driven by expanded sales teams, targeted marketing, and differentiated clinical profiles, with profitability in sight.
-
The conference highlighted a robust CNS pipeline with three commercial products and several late-stage programs, including imminent launches and regulatory milestones. Auvelity and SYMBRAVO are key growth drivers, with strong sales momentum and broad patient applicability.
-
Business remains resilient to macroeconomic risks, with strong AUVELITY growth and a robust pipeline. SYMBRAVO launch and SUNOSI's ADHD and MDD programs are advancing, while Alzheimer's agitation sNDA is on track for 3Q. Cash flow positivity is within reach.
-
Auvelity maintains strong growth with expanded sales force and a national DTC campaign planned for H2. Alzheimer's agitation sNDA is set for Q3, and Symbravo migraine launch is on track for June. Pipeline progress includes AXS-12 for narcolepsy, leveraging existing infrastructure.
-
Strong Q1 sales and expanding product launches highlight robust commercial execution, with Auvelity and Symbravo leading growth. Multiple regulatory filings and positive clinical data in CNS indications position the company for continued momentum.
-
Q1 2025 saw 62% revenue growth, driven by Auvelity and Sunosi, and the FDA approval of SYMBRAVO. Multiple late-stage pipeline advances and strong cash reserves position the company for continued growth and upcoming product launches.
-
Strong commercial growth and expanded coverage for Auvelity, with new product launches and clinical milestones ahead. Regulatory progress includes upcoming sNDA for Alzheimer's agitation and new trials in smoking cessation and migraine. Key phase III data readouts are imminent.
-
Strong commercial growth in 2024, with nearly $400M in sales and new product approvals. Multiple NDA submissions and pivotal trial readouts are expected in 2024, including for Alzheimer's agitation, narcolepsy, fibromyalgia, MDD, and ADHD. Commercial and sales force expansions are underway to support launches and label extensions.
-
Symbravo received early FDA approval for acute migraine treatment in adults, demonstrating rapid and sustained efficacy with a favorable safety profile in pivotal trials. The product targets significant unmet needs, with a commercial launch planned in four months and blockbuster sales potential projected.
Fiscal Year 2024
-
Achieved 88% year-over-year revenue growth in 2024, driven by strong Auvelity and Sunosi performance. Preparing for multiple NDA submissions and new product launches in 2025, with a robust cash position to support continued growth.
-
ACCORD-2 showed AXS-05 significantly delayed relapse and improved agitation in Alzheimer's disease, with strong safety and tolerability. Advance II did not reach statistical significance but favored AXS-05 numerically. Experts expect AXS-05 to become a first-line option due to its efficacy and safety.
-
Q3 2024 saw record product revenue exceeding $100 million, driven by strong Auvelity and Sunosi growth, with robust pipeline progress and multiple late-stage clinical readouts expected soon. Cash reserves are sufficient to fund operations into profitability.
-
Strong commercial growth and a robust pipeline define the outlook, with pivotal clinical readouts for Alzheimer's agitation and migraine expected by year-end. Auvelity's differentiated profile and AXS-07's regulatory progress position the company for further expansion.
-
The discussion highlighted strong commercial growth for Auvelity, with expanded prescriber reach and payer coverage, and detailed a robust late-stage CNS pipeline. Key catalysts include multiple pivotal trial readouts and NDA filings across migraine, fibromyalgia, Alzheimer's agitation, ADHD, and narcolepsy by year-end.
-
Q2 2024 saw robust revenue growth (87% YoY), led by Auvelity and Sunosi, with expanded payer coverage and strong prescription gains. Multiple late-stage CNS pipeline milestones are expected in the second half of 2024, supporting future growth.
-
The 2024 annual meeting was held virtually, with all proposals—including director elections, auditor ratification, and executive compensation—approved by shareholders. No questions were raised during the Q&A, and forward-looking statements were qualified by standard risk disclosures.
-
Auvelity continues robust growth with expanding first- and second-line use, while the late-stage pipeline targets six marketed indications by 2025. Multiple pivotal trial readouts and NDA submissions are expected in the next 12-18 months, supported by strong financials and IP.